Detalhe da pesquisa
1.
Chemoprobe-based assays of histone lysine demethylase 1A target occupation enable in vivo pharmacokinetics and pharmacodynamics studies of KDM1A inhibitors.
J Biol Chem
; 294(20): 8311-8322, 2019 05 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30804215
2.
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
Cancer Cell
; 41(12): 2136-2153.e13, 2023 12 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37995682
3.
Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons.
Exp Hematol
; 67: 60-64.e2, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30125603
4.
Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia.
Cell Rep
; 22(13): 3641-3659, 2018 03 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29590629
5.
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.
Cancer Cell
; 33(3): 495-511.e12, 2018 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29502954
6.
Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies.
Curr Pharm Des
; 23(5): 839-857, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28120717
7.
KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease.
Epigenomics
; 7(4): 609-26, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26111032
8.
The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.
Cancer Cell
; 21(4): 473-87, 2012 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-22464800